COMPARISON OF TREATMENT OUTCOME AMONG PATIENTS WITH CHRONIC MYELOID LEUKAEMIA WHO ACHIEVED COMPLETE CYTOGENETIC RESPONSE WITHIN OR AFTER ONE YEAR OF IMATINIB MESYLATE THERAPY

Irena Čojbašić, Lana Mačukanović-Golubović, Miodrag Vučić

DOI Number
-
First page
19
Last page
24

Abstract


The introduction of imatinib, as a type of targeted molecular therapy, has profoundly changed the treatment outcome of chronic myeloid leukaemia (CML). The aim of this study was to assess and compare treatment outcome among patients who achieved complete cytogenetic response (CCgR) within or after one year following initiation of imatinib therapy. A group of 42 adult patients with early chronic-phase Philadelphia-positive CML treated with imatinib mesylate therapy has been studied. In the study group CCgR has been achieved in 36/42 (85.71%) analysed patients, while in 3/42 (7.14%) patients the absence of cytogenetic response has been noted. Early CCgR has been achieved by 25/36 (69.44%) patients with response at median time of 6.9±1.9 months, while late CCgR has been achieved by 11/36 (30.56%) patients at median time of 18.75±2.4 months. Univariate analysis has identified prognostic factors for achieving early and late CCgR. Analysis of remission duration of treatment responders has shown that 21/25 (84%) patients in the group with early CCgR and 9/11 (81.81%) patients from the group with late CCgR still maintained stable remission on last cytogenetic control. The estimated 5-year survival rate was 85% for early responders and 74% for late responders. In conclusion, these results demonstrate that there are no differences in the treatment outcome, i.e. level of response, of patients with CML in relation to whether the CCgR was achieved within or after one year of imatinib therapy.

Keywords

chronic myeloid leukaemia, imatinib, prognostic factors, treatment outcome.

Full Text:

PDF

References


Deininger MW, Goldman JM, et Melo JV. The molecular biology of chronic myeloid leukaemia. Blood 2000; 96:3343–3356.

Jabbour E, Cortes JE, Giles FJ et al. Current and emerging treatment options in chronic myeloid leukaemia. Cancer 2007; 109:2171–2181.

Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia. N Engl J Med 2006; 355:2408–2417.

O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukaemia. N Engl J Med 2003; 348:994–1004.

Cortes J, Tolpaz M, O’Brien SG, et al. Molecular responses in patients with chronic myelogenous leukaemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11:3425–3432.

Jabbour E, Kantarjian HM, O’Brien SG, et al. The achievement of an early complete cytogenetic response is a major determinant of outcome in patients with early chronic phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors. Blood 2011; 118:4541–4546.

Iacobucci I, Rosti G, Amabile A, et al. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukaemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. J Clin Oncol 2006; 24:454–459.

Baccarani M, Saglio J, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European LeukaemiaNet. Blood 2006; 108:1809–1820.

Baccarani M, Cortes J, Pane FD, et al. Chronic myeloid leukaemia. An update of concepts and management Recommendations of the European LeukaemiaNet. J Clin Oncol 2009; 27:6041–6051.

Deininger M, Buchdunger E, at Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukaemia. Blood 2005; 105:2640–2653.

Guilhot F, Druker B, Larson RA, et al. High rates of durable response are achieved with imatinib after treatment with interferon-alfa plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica 2009; 94:1669–1675.

Hochhaus A, O’Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukaemia. Leukaemia 2009; 23:1054–1061.

Deininger M, O’Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114:1126–1127.

Cortes J. Natural history and staging of chronic myelogenous leukaemia. Hematol Oncol Clin North Am 2004; 18:569–584.

Kantarjian HM, Cortes EJ, O’Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukaemia after failure of interferon-alfa. Blood 2004; 104:1079–1088.

Kantarjian HM, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate versus interferon alfa-based regimens in newly diagnosed chronic-phase chronic myelogenous leukaemia. Blood 2006; 108:1835–1840.

Cardema A, Kantarjian HM, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukaemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood 2009; 113:6315–6321.


Refbacks

  • There are currently no refbacks.


© University of Niš, Serbia
Creative Commons licence CC BY-NC-ND
ISSN 0354-4699 (Print)
ISSN 2406-050X (Online)